PSTX - Poseida Therapeutics, Inc.

0   0%

Share volume: 0
Last Updated:
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.07%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
N/A
P/E Ratio 
N/A
DAY RANGE
N/A - N/A
EPS 
N/A
52 WEEK RANGE
N/A - N/A
52 WEEK CHANGE
N/A
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Mark J. Gergen
Region: US
Website: poseida.com
Employees: 260
IPO year: 2020
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC)

Recent news
loading